These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31419168)

  • 21. National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Aug; 61(34):671-7. PubMed ID: 22932301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Aug; 60(30):1018-9. PubMed ID: 21814165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
    Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
    Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
    Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
    Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015.
    Reagan-Steiner S; Yankey D; Jeyarajah J; Elam-Evans LD; Curtis CR; MacNeil J; Markowitz LE; Singleton JA
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(33):850-8. PubMed ID: 27561081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Associated With Receipt of Meningococcal B Vaccine Among United States Adolescents, National Immunization Survey-Teen, 2017-2018.
    Hansen CE; Niccolai LM
    J Adolesc Health; 2021 Nov; 69(5):769-773. PubMed ID: 34148798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National and State-Level Composite Completion of Recommended Vaccines Among Adolescents in the United States, 2015-2018.
    La EM; Garbinsky D; Hunter S; Poston S; Novy P; Ghaswalla P
    J Adolesc Health; 2021 Nov; 69(5):762-768. PubMed ID: 34518068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
    Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
    Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).
    Robertson CA; Hedrick J; Bassily E; Greenberg DP
    Vaccine; 2019 Feb; 37(8):1016-1020. PubMed ID: 30670301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of Use of Human Papillomavirus and Other Adolescent Vaccines in the United States.
    Vielot NA; Butler AM; Brookhart MA; Becker-Dreps S; Smith JS
    J Adolesc Health; 2017 Sep; 61(3):281-287. PubMed ID: 28739327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
    Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
    Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
    Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.